Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Inclusion Criteria:

1. Diagnosis of SSc based on ACR/ EULAR criteria (2013)

2. Overall duration of SSc < 84 months from the first non-Raynaud symptom manifestationprior to Day 1

3. HRCT obtained at the Screening Visit or within the 3 months prior to Screeningconsistent with SSc-ILD (adjudicated by a central reader) AND with pulmonaryinvolvement > 10%

4. Clinical presentation at Screening consistent with lcSSc (up to 40% of patients) ordcSSc

5. MMF of ≥ 2 gm/day (or equivalent doses of other mycophenolate based compounds) for 3months prior to Day 1 OR When documented intolerance to mycophenolates (indiscussion with the Medical Monitor): treatment with maximum tolerated dose of MMFis acceptable, if < 2 gm/day, provided the cumulative duration of dosing hasexceeded 3 months, OR An adequate dose and duration of an alternateimmunosuppressant with a stable dose for the 4 weeks prior to baseline is alsoallowed.

Exclusion Criteria:

1. Pulmonary disease with FVC %pred ≤ 45% OR DLco %pred ≤ 30%; FEV1/FVC ratio < 0.7

2. Participants with pulmonary artery hypertension on parenteral therapy or withclinical evidence of right heart failure

3. HRCT obtained in the 3 months prior to Screening consistent with other confoundingpathology.

4. Treatment with corticosteroids (> 10 mg/day of prednisone or equivalent) within 2weeks prior to Day 1

5. Treatment with more than 1 immunosuppressant (e.g., MMF, methotrexate [MTX],azathioprine [AZA], or leflunomide)

6. Any treatment in the 12 months prior to Day 1 with any of the following: rituximab,intravenous immune globulin (IVIG), tocilizumab, cyclophosphamide, pirfenidone,tyrosine-kinase inhibitors (e.g., imatinib, nilotinib, dasatinib)

7. Rheumatic autoimmune disease other than SSc, Is an active, heavy smoker oftobacco/nicotine-containing products

8. History of (anti-Jo-1) anti-synthetase syndrome or Jo-1 positive at Screening